U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 6 of 6 results

Status:
US Approved Rx (2006)
First approved in 2006

Class (Stereo):
CHEMICAL (ACHIRAL)



Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



LY-3009120 is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf, and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3...
Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cholanic acid is the archetypal C24 bile acid skeleton from which all other C24 bile acids can be derived. Of the two common isomers: 5alpha and 5Beta, the last isomer is the most biologically relevant. 5-Beta Cholanic Acid has been studied as a mo...
Status:
US Approved Rx (2006)
First approved in 2006

Class (Stereo):
CHEMICAL (ACHIRAL)



Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...
Status:
US Approved Rx (2006)
First approved in 2006

Class (Stereo):
CHEMICAL (ACHIRAL)



Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...